Novartis in advanced talks to buy Cytokinetics: Source Ruchika Sharma10 Jan 2024 3:30 PM ISTAccess to Cytokinetics products would help Novartis offset the expected loss of U.S. exclusivity of Entresto, its key drug in this field, said...
Aficamten improved outcomes for patients with obstructive hypertrophic cardiomyopathy: Phase 3 SEQUOIA-HCM trial Medha Baranwal29 Dec 2023 7:30 PM ISTUSA: The pivotal Phase 3 clinical trial (SEQUOIA-HCM) of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) has...
Low Thyroid Hormone Levels Linked to Increased Risk of Adverse Events in Hypertrophic Cardiomyopathy Patients Dr Riya Dave26 Sept 2023 8:00 PM ISTHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder known for its association with sudden cardiac death and progressive heart...
Valsartan fails to slow cardiac remodeling among patients of subclinical HCM: JAMA Medha Baranwal14 Sept 2023 9:45 AM ISTUSA: Recent findings from the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial published in...
Mavacamten Shows Promise in Reducing Need for Invasive Treatment in Hypertrophic Cardiomyopathy Patients Dr. Kamal Kant Kohli6 Sept 2023 11:15 AM ISTPatients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM) often face a challenging dilemma: whether to opt for invasive...
ESC 2023 Update: First international guidelines on heart muscle diseases published today Dr. Kamal Kant Kohli28 Aug 2023 9:30 AM ISTThe European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online today in European Heart Journal. This is the first...
Pregnancy may not have long term adverse outcomes in women with hypertrophic cardiomyopathy Niveditha Subramani19 Aug 2023 11:45 AM ISTHypertrophic cardiomyopathy (HCM) is a common condition affecting the left ventricle, the main pumping chamber of the heart. The walls of the left...
Bristol Myers Squibb bags European Commission nod for heart disease treatment Camzyos Ruchika Sharma27 Jun 2023 11:31 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg,...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for CAMZYOS for treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Ruchika Sharma30 April 2023 12:15 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Extended ECG monitoring detects more arrhythmias in patients with hypertrophic cardiomyopathy Dr. Kamal Kant Kohli21 April 2023 10:15 AM ISTSpain: Extended ECG (electrocardiogram) monitoring (30 days) compared to the standard 24 to 48 hours detects more arrhythmias in patients with...
Complications of alcohol septal ablation for HCM not tied to worse outcomes Medha Baranwal13 April 2023 8:00 PM ISTCzech Republic: The occurrence of high-grade conduction disturbances in patients with obstructive hypertrophic cardiomyopathy (HCM) treated with...
AHA's scientific statement guides clinicians on what to do after genetic tests unexpectedly find genes linked to heart disease Dr. Kamal Kant Kohli30 March 2023 8:00 PM ISTUSA: A new scientific statement released by the American Heart Association (AHA) aims to guide clinicians who are called on to evaluate patients with...
